Fournier’s Gangrene and Sodium-Glucose Co-Transporter-2 Inhibitors: A Critical Combination in the Critical Care Unit
Abstract
This paper describes the holistic management and contribution of critical care to the successful treatment of the life-threatening condition, Fournier’s gangrene, in patients prescribed sodium-glucose co-transporter-2 (SGLT2) inhibitors, using a case report for illustration. A gentleman in his 70s, prescribed empagliflozin, an SGLT2 inhibitor for managing his diabetes and heart failure, presented in a moribund state to the Emergency Department. The interplay of his co-morbidities and medication regimen created a scenario that heightened his risk of developing the life threatening condition of Fournier’s gangrene, which was successfully managed. We highlight several critical considerations for a favorable outcome in the setting of critical care. A comprehensive system approach with awareness of the risks associated with SGLT2 inhibitor therapy is crucial to effectively managing Fournier’s gangrene in critical care.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.